Navigation Links
ANX in Medical News

ADVENTRX Pharmaceuticals Announces Closing of Financing

... SAN DIEGO, July 6 /PRNewswire-FirstCall/ -- ADVENTRX Pharmaceuticals, Inc. (NYSE Amex: anx ) announced today that it has completed the previously announced sale of shares of its 5% Series B convertible preferred stock pursuant to a registere...

ADVENTRX Grants Exclusive Rights to ANX-514 in South Korea

...h 25 /PRNewswire-FirstCall/ -- ADVENTRX Pharmaceuticals, Inc. (NYSE Amex: anx ) announced today that it has granted Shin Poong Pharmaceutical Co., Ltd. (...ted Mr. Byung Hwa Kim, Chief Executive Officer of Shin Poong. About anx -514 (docetaxel emulsion) ANX-514 is a novel nano-emulsion formulation ...

ADVENTRX Pharmaceuticals to Report Third Quarter 2008 Results

... simultaneous webcast at http://www.adventrx.com SAN DIEGO, Oct. 30 /PRNewswire-FirstCall/ -- ADVENTRX Pharmaceuticals, Inc. (Amex: anx ) today announced that it will host a conference call with simultaneous webcast to discuss third quarter 2008 results on Thursday, November 6th, 2008 ...

ADVENTRX Pharmaceuticals Reports Second Quarter 2008 Financial Results and Business Update

... simultaneous webcast at http://www.adventrx.com SAN DIEGO, Aug. 11 /PRNewswire-FirstCall/ -- ADVENTRX Pharmaceuticals, Inc. (Amex: anx ), a biopharmaceutical company focused on in-licensing, developing and commercializing proprietary product candidates primarily for the treatment of c...

ADVENTRX Pharmaceuticals to Report First Quarter 2008 Results

...fic); simultaneous webcast at http://www.adventrx.com SAN DIEGO, May 5 /PRNewswire-FirstCall/ -- ADVENTRX Pharmaceuticals, Inc. (Amex: anx ) today announced that it will host a conference call with simultaneous webcast to discuss first quarter 2008 results on Monday, May 12th, 2008 at 1:3...

QED International Associates Announces Quarterly Rebalancing of HealthShares(TM) Indexes

...uker Corporation (Nasdaq: BRKR ) Halozyme Therapeutic (Nasdaq: HALO ) Emerging Cancer Index (HHJ) Drop Adventrx Pharmaceuticals, Inc. (Amex: anx ) Keryx Biopharmaceuticals, Inc. (Nasdaq: KERX ) Add Dyanvax Technologies (Nasdaq: DVAX ) Synta Pharmaceuticals Corp. (Nasdaq: SNTA ) Enab...

ADVENTRX Pharmaceuticals to Present at The 10th Annual BIO CEO & Investor Conference

... SAN DIEGO, Feb. 5 /PRNewswire-FirstCall/ -- ADVENTRX Pharmaceuticals, Inc. (Amex: anx ), a biopharmaceutical research and development company focused on commercializing proprietary product candidates for the treatment of cancer and infe...

ADVENTRX Pharmaceuticals to Present at the 2007 RBC Capital Markets Healthcare Conference

... SAN DIEGO, Dec. 10 /PRNewswire-FirstCall/ -- ADVENTRX Pharmaceuticals, Inc. (Amex: anx ), a biopharmaceutical research and development company focused on commercializing proprietary product candidates for the treatment of cancer and infe...

ADVENTRX Pharmaceuticals to Present at the 13th Annual BIO-Europe Partnering Conference

... SAN DIEGO, Nov. 5 /PRNewswire-FirstCall/ -- ADVENTRX Pharmaceuticals, Inc. (Amex: anx ), a biopharmaceutical research and development company focused on commercializing proprietary product candidates for the treatment of cancer and infe...

ADVENTRX Pharmaceuticals to Present at the 18th Annual CIBC Healthcare Conference

... SAN DIEGO, Oct. 31 /PRNewswire-FirstCall/ -- ADVENTRX Pharmaceuticals, Inc. (Amex: anx ), a biopharmaceutical research and development company focused on commercializing proprietary product candidates for the treatment of cancer and infe...

More>>

ANX in Medical Technology

ADVENTRX Announces Results From ANX-514 Bioequivalence Study

... Updates guidance regarding strategic transaction process SAN DIEGO, May 7 /PRNewswire-FirstCall/ -- ADVENTRX Pharmaceuticals, Inc. (NYSE Amex: anx ) today announced results from its bioequivalence study of ANX-514 (docetaxel emulsion). ANX-514 was determined to have comparable overall safety as ...

ADVENTRX Announces Preliminary Response Rate Data From Discontinued Phase 3 Trial of CoFactor(R)

... SAN DIEGO, July 1 /PRNewswire-FirstCall/ -- ADVENTRX Pharmaceuticals, Inc. (Amex: anx ) today announced preliminary response rate results from its discontinued Phase 3 clinical trial of ANX-510, or CoFactor, the Company's folate-based b...

ADVENTRX Announces CoFactor(R) Phase 2b Clinical Trial Overall Survival Results

... SAN DIEGO, June 16 /PRNewswire-FirstCall/ -- ADVENTRX Pharmaceuticals, Inc. (Amex: anx ) today provided an update with regard to overall survival from its Phase 2b clinical trial of CoFactor for the treatment of first-line metastatic col...

ADVENTRX Presents CoFactor Data at the 2008 Annual Meeting of the American Society of Clinical Oncology (ASCO)

... SAN DIEGO, June 3 /PRNewswire-FirstCall/ -- ADVENTRX Pharmaceuticals, Inc. (Amex: anx ) announced today that it presented objective response rate and available safety data from the Company's Phase 2 clinical study of ANX-510, or CoFacto...

ADVENTRX Announces ANX-530 Safety Data From Registrational Bioequivalence Clinical Study

...e American Society of Clinical Oncology SAN DIEGO, May 16 /PRNewswire-FirstCall/ -- ADVENTRX Pharmaceuticals, Inc. (Amex: anx ) announced today that, in a registrational bioequivalence clinical study, ANX-530 demonstrated a statistically significant reduction in general disor...

ANX-201 Demonstrates a Unique Resistance Profile in Preclinical Tests

...esents Results at Keystone Symposia HIV Pathogenesis Conference SAN DIEGO, March 31 /PRNewswire-FirstCall/ -- ADVENTRX Pharmaceuticals, Inc. (Amex: anx ) announced that it presented preclinical results for ANX-201, the Company's broad-spectrum antiviral product candidate at the Keystone Symposia HIV P...

ADVENTRX to Present CoFactor Phase 2 Breast Cancer Data at the 2008 Annual Meeting of the American Society of Clinical Oncology (ASCO)

... SAN DIEGO, March 12 /PRNewswire-FirstCall/ -- ADVENTRX Pharmaceuticals, Inc. (Amex: anx ) announced today that preliminary data from the Company's Phase 2 clinical study of ANX-510, CoFactor(R), for the treatment of advanced breast cancer...

ADVENTRX to Present ANX-201 Preclinical Data at Keystone Symposia HIV Pathogenesis Conference

... SAN DIEGO, Jan. 31 /PRNewswire-FirstCall/ -- ADVENTRX Pharmaceuticals, Inc. (Amex: anx ), announced today that data from preclinical studies of ANX-201, the Company's broad spectrum antiviral product candidate, has been accepted for pres...

ADVENTRX Announces Completion of Patient Enrollment in Phase 2 Clinical Trial of CoFactor(R) for the Treatment of Advanced Breast Cancer

... SAN DIEGO, Dec. 5 /PRNewswire-FirstCall/ -- ADVENTRX Pharmaceuticals, Inc. (Amex: anx ), a biopharmaceutical research and development company focused on commercializing proprietary product candidates for the treatment of cancer and infe...

ADVENTRX Meets Primary Endpoint in ANX-530 Marketing-Enabling Clinical Study

... SAN DIEGO, Nov. 16 /PRNewswire-FirstCall/ -- ADVENTRX Pharmaceuticals, Inc. (Amex: anx ) today announced positive results from its marketing-enabling clinical study of ANX-530 (vinorelbine emulsion). Pharmacokinetic equivalence, the prim...
ANX in Biological Technology

ADVENTRX to Hold Second Quarter Results and Business Update Conference Call on August 12

... SAN DIEGO, Aug. 5 /PRNewswire-FirstCall/ -- ADVENTRX Pharmaceuticals, Inc. (NYSE Amex: anx ) today announced that it will hold a conference call on Wednesday, August 12, 2009 at 1:30 p.m. Pacific (4:30 p.m. Eastern) to review financial resul...

ADVENTRX Pharmaceuticals Announces Financing

... SAN DIEGO, Aug. 5 /PRNewswire-FirstCall/ -- ADVENTRX Pharmaceuticals, Inc. (NYSE Amex: anx ) announced today that it has obtained a commitment to purchase shares of convertible preferred stock pursuant to a registered direct offering to a si...

ADVENTRX Pharmaceuticals Announces Plans for Remainder of 2009

...nal manufacturing activities for ANX-530 NDA re-started SAN DIEGO, June 29 /PRNewswire-FirstCall/ -- ADVENTRX Pharmaceuticals, Inc. (NYSE Amex: anx ) today announced its plans for the remainder of 2009. Following the financing that closed earlier this month, ADVENTRX has re-started the fina...

ADVENTRX Pharmaceuticals Announces Closing of Financing

... SAN DIEGO, June 15 /PRNewswire-FirstCall/ -- ADVENTRX Pharmaceuticals, Inc. (NYSE Amex: anx ) today announced that it has completed the previously announced sale of shares of convertible preferred stock pursuant to a registered direct offerin...

ADVENTRX Pharmaceuticals Announces Financing

... SAN DIEGO, June 8 /PRNewswire-FirstCall/ -- ADVENTRX Pharmaceuticals, Inc. (NYSE Amex: anx ) announced today that it has obtained a commitment to purchase shares of convertible preferred stock pursuant to a registered direct offering to a si...

ADVENTRX Pharmaceuticals, Inc. Reports Fourth Quarter and Full Year 2008 Financial Results

... SAN DIEGO, March 25 /PRNewswire-FirstCall/ -- ADVENTRX Pharmaceuticals, Inc. (NYSE Amex: anx ) today reported financial results for the fourth quarter and year ended December 31, 2008. "2008 was a transition year for ADVENTRX in which we ...

ADVENTRX Announces Further Cost-Cutting Measures

... SAN DIEGO, March 20 /PRNewswire-FirstCall/ -- ADVENTRX Pharmaceuticals, Inc. (NYSE Amex: anx ) announced today that, effective April 3, it will reduce its full-time workforce to five employees and will discontinue substantially all of its deve...

ADVENTRX Exploring Strategic Options

..., Dec. 15 /PRNewswire-FirstCall/ -- ADVENTRX Pharmaceuticals, Inc. (Amex: anx ), a biopharmaceutical company focused on in-licensing, developing and comm...velopment and commercialization of its lead product candidates, ANX-530 and anx 514; the risk that ADVENTRX's stockholders will not approve a transaction r...

ADVENTRX Pharmaceuticals Reports Third Quarter 2008 Financial Results and Business Update

...GO, Nov. 6 /PRNewswire-FirstCall/ -- ADVENTRX Pharmaceuticals, Inc. (Amex: anx ), a biopharmaceutical company focused on in-licensing, developing and comm...uding funding the continued development and commercialization of ANX-530 or anx 514; the risk that restructuring costs may be greater than anticipated and ...

ADVENTRX Pharmaceuticals to Present at the Rodman & Renshaw 10th Annual Global Healthcare Conference

... SAN DIEGO, Nov. 4 /PRNewswire-FirstCall/ -- ADVENTRX Pharmaceuticals, Inc. (Amex: anx ) today announced that Mark Erwin, Senior Vice President, Operations of ADVENTRX, is scheduled to present at the Rodman & Renshaw 10th Annual Global H...
Other Tags
(Date:7/28/2014)... that they monopolize large amounts of sugar. More recently, ... characterized by a series of features such as mobility ... are calling this behavior "mesenchymal," and they suspect it ... was able to demonstrate that the two observations ... the same mechanism, at least in "non-small cell lung ...
(Date:7/28/2014)... 29, 2014 The “Tissue ... Hybridization, Digital pathology & Workflow, Special Staining), ... Cancer, Non Small Cell Lung Cancer and ... Pharmaceutical companies, Research Laboratories, Contract Research Organizations ... Europe, BRIC, Japan & RoW) - Trends ...
(Date:7/28/2014)... TX (PRWEB) July 28, 2014 A lush ... family playtime during the summer. However, the summer heat, lack ... lawn to become brown, weak and unhealthy. The Grounds Guys ... It Grow, Mow a lawn once a week and set ... than normal. This protects the grass roots from heat and ...
(Date:7/28/2014)... UHY LLP, a member of the ... UHY International Business – Issue 29. This bi-annual publication ... most current business challenges and key issues faced by ... the following topics:, , Key industry ... over the next five years? Where are growth opportunities ...
(Date:7/28/2014)... 2014 Dawn Echols’ professional background ... and music. This experience has honed her people ... psychology. Her professional counseling ( http://dawningphoenix.com ) work ... for offenders in domestic violence. , As ... she enjoys counseling individuals and groups for a ...
Breaking Medicine News(10 mins):Health News:Cancer: Tumors absorb sugar for mobility 2Health News:Advanced Cancer Diagnostics Market Worth $3,924.01 Million by 2018 - New Report by MarketsandMarkets 2Health News:Advanced Cancer Diagnostics Market Worth $3,924.01 Million by 2018 - New Report by MarketsandMarkets 3Health News:Advanced Cancer Diagnostics Market Worth $3,924.01 Million by 2018 - New Report by MarketsandMarkets 4Health News:Advanced Cancer Diagnostics Market Worth $3,924.01 Million by 2018 - New Report by MarketsandMarkets 5Health News:Nurturing Lawns in the Summer Heat: The Grounds Guys® Offers Tips on Caring for Lawns This Summer 2Health News:Uhy International Business Issue 29 Now Available 2Health News:Uhy International Business Issue 29 Now Available 3Health News:Dawn M. Echols, M.S., LPC of Dawning Phoenix Speaks at Newly Formed Task Force 2
(Date:7/28/2014)... the bug hunter, but the target of his work ... identified with special methods and instruments. Benjamin Hause, an ... Laboratory at Kansas State University, recently published an article ... is an important find in the United States. , ... know what it was," Hause said. "We used next-generation ...
(Date:7/28/2014)... that can help advance the genetic engineering of ... has been developed by researchers with the U.S. ... a multi-institutional partnership led by Lawrence Berkeley National ... an assay that enables scientists to identify and ... components in the biosynthesis of plant cell walls. ...
(Date:7/28/2014)... for Biologically Inspired Engineering at Harvard University today ... commercialized by a newly formed private company to ... medicine products. The announcement follows a ... Development (OTD) and the start-up Emulate Inc., relating ... Organs-on-Chips platform. , "This is a big ...
Breaking Biology News(10 mins):Researcher using next-generation sequencing to rapidly identify pathogens 2Researcher using next-generation sequencing to rapidly identify pathogens 3How sweet it is 2How sweet it is 3Wyss Institute's technology translation engine launches 'Organs-on-Chips' company 2Wyss Institute's technology translation engine launches 'Organs-on-Chips' company 3
Other Contents